Company
Headquarters: Molndal, Sweden
Employees: 9
CEO: Ms. Karin Fischer
kr35.7 Million
SEK as of Jan. 1, 2024
US$3.5 Million
Company | Market Cap (USD) |
---|---|
Zoetis Inc. | $89.09 B |
MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
Takeda Pharmaceutical Company Limited | $47.71 B |
Haleon plc | $38.90 B |
PPD, Inc. | $16.58 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
RLS Global AB (publ), a medical technology company, develops and sells products for the treatment of illnesses in wound and oral care in Sweden. Its products include ChloraSolv that is used for the treatment of chronic diabetic foot and leg ulcers for diabetic patients; and CariSolv, a gel used for removing caries. The company was founded in 1996 and is based in Mölndal, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
RLS Global AB has the following listings and related stock indices.
Stock: OMX: RLS wb_incandescent